ConductScience.org, home
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
API referenceFor AI assistants

Trial · NCT03123783

Participant flow70

How many started, completed or left each group, period by period.

41 to 60 of 70

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Phase 2STARTEDCohort 3A(Arm)/ PD1-NSCLC (Phase 2)14
Phase 2STARTEDCohort 3B(Arm)/ PD1-NSCLC (Phase 2)28
Phase 2Phase 2 Participants in Safety PopulationDL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b)0
Phase 2Phase 2 Participants in Safety PopulationDL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b)0
Phase 2Phase 2 Participants in Safety PopulationDL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b)0
Phase 2Phase 2 Participants in Safety PopulationCohort 1(Arm)/ inNSCLC (Phase 2)53
Phase 2Phase 2 Participants in Safety PopulationCohort 2(Arm)/ PD1-MM (Phase 2) -38
Phase 2Phase 2 Participants in Safety PopulationCohort 3A(Arm)/ PD1-NSCLC (Phase 2)14
Phase 2Phase 2 Participants in Safety PopulationCohort 3B(Arm)/ PD1-NSCLC (Phase 2)28
Phase 2Phase 2 Participants in the Efficacy (EE) PopulationDL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b)0
Phase 2Phase 2 Participants in the Efficacy (EE) PopulationDL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b)0
Phase 2Phase 2 Participants in the Efficacy (EE) PopulationDL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b)0
Phase 2Phase 2 Participants in the Efficacy (EE) PopulationCohort 1(Arm)/ inNSCLC (Phase 2)48
Phase 2Phase 2 Participants in the Efficacy (EE) PopulationCohort 2(Arm)/ PD1-MM (Phase 2) -33
Phase 2Phase 2 Participants in the Efficacy (EE) PopulationCohort 3A(Arm)/ PD1-NSCLC (Phase 2)12
Phase 2Phase 2 Participants in the Efficacy (EE) PopulationCohort 3B(Arm)/ PD1-NSCLC (Phase 2)25
Phase 2COMPLETEDDL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b)0
Phase 2COMPLETEDDL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b)0
Phase 2COMPLETEDDL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b)0
Phase 2COMPLETEDCohort 1(Arm)/ inNSCLC (Phase 2)48

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous pageNext page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03123783/flow?page=3

API referenceFor AI assistants